By Fineline Cube Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), co-developed with Bristol-Myers Squibb (BMS), has received approval from China’s National Medical Products Administration (NMPA) to proceed with clinical studies in locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive driver genes.
Development & Regulatory Milestone
| Parameter | Detail |
|---|---|
| Company | Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) |
| Partner | Bristol-Myers Squibb |
| Drug | Izalontamab brengitecan (iza-bren) |
| Drug Class | First-in-class bispecific antibody-drug conjugate (ADC) |
| New Indication | NSCLC with positive driver genes (combination therapy) |
| Global Clinical Program | 40+ clinical studies across multiple tumor types |
| Breakthrough Therapy Designations | 7 (China) + 1 (US) |
Drug Profile & Clinical Strategy
Novel Bispecific ADC Platform
Iza-bren represents a first-in-class, new-concept therapeutic leveraging bispecific antibody technology combined with cytotoxic payload delivery, designed to:
- Target multiple tumor-associated antigens simultaneously
- Enhance tumor specificity and payload delivery
- Overcome resistance mechanisms seen with single-target agents
- Provide synergistic anti-tumor activity in combination regimens
Expanded Clinical Development
The newly approved study will evaluate iza-bren in combination with other drugs specifically in:
- Locally advanced or metastatic NSCLC
- Patients with positive driver gene mutations
- Setting builds on established safety profile from ongoing global trials
Priority Review Pipeline
Beyond the newly approved NSCLC indication, iza-bren is currently under priority review in China for two additional indications:
| Indication | Status | Market Significance |
|---|---|---|
| Locally advanced or metastatic nasopharyngeal carcinoma | Priority review | High prevalence in Asia-Pacific region |
| Recurrent or metastatic esophageal squamous cell carcinoma | Priority review | Significant unmet need in gastrointestinal oncology |
Strategic Partnership Impact
For Sichuan Biokin
- Global validation: BMS partnership provides international credibility and development resources
- Platform expansion: Success in multiple tumor types validates bispecific ADC platform
- Commercial potential: Multiple priority reviews position for rapid market entry across indications
For Bristol-Myers Squibb
- Innovation pipeline: Access to novel bispecific ADC technology from Chinese biotech leader
- Asia-Pacific strategy: Strengthened position in high-growth Chinese oncology market
- Combination opportunities: Potential to pair with BMS’s existing immuno-oncology portfolio
Market Context & Competitive Landscape
- ADC Market Growth: Global ADC market projected to reach $16.4 billion by 2028, with China representing fastest-growing segment
- NSCLC Treatment Gap: Despite advances in targeted therapy, significant unmet need remains for patients with driver-positive disease progressing on current regimens
- Chinese Innovation Leadership: Sichuan Biokin exemplifies China’s evolution from generic manufacturer to innovative biologics developer
- Regulatory Acceleration: Breakthrough Therapy Designations and priority reviews reflect NMPA’s commitment to expediting innovative cancer therapies
The expanded clinical program positions iza-bren as a multi-indication oncology asset with potential to address significant unmet needs across multiple solid tumor types.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential for iza-bren. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech